PEB
10/04/2015 11:06
GENERAL
NOT PRICE SENSITIVE
REL: 1106 HRS Pacific Edge Limited
GENERAL: PEB: Cxbladder Triage paper published- international med journal
10 April 2015
Cxbladder Triage paper published in international medical journal
Dunedin-based Pacific Edge said today that its research paper on Cxbladder
Triage had now been published in the internationally leading medical journal
BioMed Central ("BMC") Urology.
Chief Executive David Darling said: "This is a significant milestone for the
company as it profiles our latest bladder cancer product to a global
audience."
The research paper can be viewed by clicking on the following link:
http://www.biomedcentral.com/content/pdf/s12894-015-0018-5.pdf
"Publication in BMC Urology is an open access journal, available online, and
as such is a quick and efficient way of reaching a large international
audience including the people who make treatment decisions for patients and
for the payers who fund such treatment. It is also part of our strategy of
making the product available in the USA this year," David Darling added.
Cxbladder Triage, the second product in its suite of diagnostic tests for the
detection and management of bladder cancer, was launched at the end of last
year in New Zealand. "It takes us a step closer to our vision of a
'one-stop-shop' for bladder cancer detection and management," says David
Darling.
Cxbladder Triage complements the first molecular diagnostic test Cxbladder
Detect and will enable clinicians and physicians to accurately segregate
patients who present with haematuria, who have a low probability of having
bladder cancer. Potentially this will save many patients from undergoing an
expensive and invasive investigation for bladder cancer.
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.
www.pacificedge.co.nz www.pacificedgedx.com
ABOUT Cxbladder Detect
Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
New Zealand, Australia and the USA. Cxbladder Detect is available in the USA
and NZ as a laboroatory Developed Test (LDT) from the company's CLIA
certified laboratories, providing physicians and clinicians with a quick,
cost effective and accurate measure of the presence of the cancer, and
provides urologists with the opportunity to reduce their reliance on the need
for invasive tests such as cystoscopy. The Cxbladder Detect cancer detection
test has been validated by a multicentre, international clinical study.
www.cxbladder.com
ABOUT Cxbladder Triage
Cxbladder Triage is a novel molecular test that combines the power of the
genomic biomarkers with extra phenotypic biomarkers to accurately identify
and remove patients with haematuria who have a low probability of bladder
cancer, from needing to have a full-urological work-up. This is a tool for
use by clinicians and physicians in the primary evaluation and will result
in a reduction of the number of patients needing an expensive and invasive
work-up for urothelial cancer.
www.cxbladder.com
ABOUT BLADDER CANCER
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist.
Bladder cancer has a very high recurrence rate of approximately 50%-70% with
up to 30% of these recurring as later stage tumours. However, bladder cancers
are highly treatable, especially if detected in the early stages when there
is a much higher probability of survival. Timely detection and regular
surveillance and monitoring of this cancer is a key element of the clinical
process and of the individual's annual healthcare plan.
End CA:00262960 For:PEB Type:GENERAL Time:2015-04-10 11:06:07
